Molecular pathogenesis, treatment strategies and animal models of Alzheimer's disease

Chinese Pharmaceutical Journal

Volumn 54, Issue 1, 2002, Pages 1-16

  Shiao, Young Ji ^a   Wang, Chuen Neu ^a  

^a NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

Alzheimer's disease; Amyloid ; Animal model; Neurotoxicity

Indexed keywords

BRAIN; NEUROLOGY; PROTEINS; TOXICITY;

SENILE PLAQUES;

DISEASES;

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; APIGENIN; APOLIPOPROTEIN E4; ASPARTIC PROTEINASE; BETA SECRETASE; CALCIUM CHANNEL BLOCKING AGENT; CASPASE; CASPASE INHIBITOR; CD11B ANTIGEN; CD45 ANTIGEN; CHOLESTEROL; COMPLEMENT RECEPTOR; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYTOKINE; FLAVONOID; GAMMA SECRETASE; GROWTH FACTOR; IMMUNOGLOBULIN RECEPTOR; KAEMPFEROL; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTOESTROGEN; PRESENILIN 1; PRESENILIN 2; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; SCAVENGER; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; APOPTOSIS; CALCIUM HOMEOSTASIS; IN VITRO STUDY; NERVE CELL NECROSIS; NEUROFILAMENT; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOGENESIS; REVIEW; SENILE PLAQUE; TRANSGENIC MOUSE;

EID: 0036259370     PISSN: 10161015     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (139)

1. Life and death of neurons in the aging brain
2. Genetic neurodegenerative disease: The human illness and transgenic models
3. Deciphering Alzheimer's disease: The amyloid precursor protein yields new clues
4. Alzheimer disease
5. Regulation of APP processing by intra- and intercellular signals"
6. Amyloid β-protein and the genetics of Alzheimer's disease
7. The toxicity in vitro of β-amyloid protein
8. Aggregated amyloid-β protein induces cortical neuronal apoptosis and concomitant "apoptotic" pattern of gene induction
9. Selective phosphorylation of adult tau isoforms in mature hippocampal neurons exposed to fibrillar Aβ
10. Amyloid β-peptide induces apoptosis-related events in synapses and dendrites
11. Mechanisms of neuronal degeneration in Alzheimer's disease
12. Apoptosis is induced by β-amyloid in cultured central nervous system neurons
13. Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction
14. 2+ homeostasis and cell death
15. Activation of the L voltage-sensitive calcium channel by Mitogen-Activated Protein (MAP) kinase following exposure of neuronal cells to β-amyloid. MAP kinase mediates β-amyloid-induced neurodegeneration
16. 2+ channel activity by β-amyloid-(1-40) in rat cortical synaptosomes and cultured
17. Mitochondrial manganese superoxide dismutase prevents neural apoptosis and reduces ischemic brain injury: Suppression of peroxynitrite production, lipid peroxidation, and mitochondrial dysfunction
18. β-amyloid neurotoxicity in vitro: Evidence of oxidative stress but not protection by antioxidants"
19. Hydrogen peroxide mediates amyloid beta protein toxicity
20. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide
21. Activation of caspase-3 in β-amyloid-induced apoptosis of cultured rat cortical neurons
22. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β
23. Caspase-2 mediates neuronal cell death induced by β-amyloid
24. E2F1 mediates death of β-amyloid-treated cortical neurons in a manner independent of P53 and dependent on bax and caspase 3"
25. The neuroprotective effects of phytoestrogens on amyloid β protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons
26. Involvement of cell cycle elements, cyclin-dependent kinases, Prb, and E2F X DP, in β-amyloid-induced neuronal death
27. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
28. Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production
29. Release of excess amyloid β-protein from a mutant amyloid β-protein precursor"
30. β-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
31. Purification and cloning of amyloid precursor protein β-secretase from human brain
32. Membrane-anchored aspartyl protease with Alzheimer's disease β-secretase activity
33. Identification of a novel aspartic protease (asp 2) as β-secretase
34. Human aspartic protease memapsin 2 cleaves the β-secretase site of β-amyloid precursor protein
35. A portrait of Alzheimer secretase-new familiar faces
36. Cleavage of amyloid β peptide during constitutive processing of its precursor"
37. Evidence that β-amyloid protein in Alzheimer's disease is not derived by normal processing
38. Activation of protein kinase C inhibits cellular production of the amyloid β-protein
39. Protein phosphorylation inhibits production of Alzheimer amyloid β/A4 peptide
40. Reversal of the Swedish familial Alzheimer's disease mutant phenotype in cultured cells treated with phorbol 12,13-dibutyrate
41. The release of Alzheimer's disease β amyloid peptide is reduced by phorbol treatment"
42. Amyloid precursor protein processing is stimulated by metabotropic glutamate receptors
43. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors
44. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion andamyl-old β-protein production in human neuronal NT2N cells
45. Changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation
46. Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice
47. Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metallo-protease
48. Mechanism of the cleavage specificity of Alzheimer's disease γ-secretase identified by phenylalanine- scanning mutagenesis of the transmembrane domain of the amyloid precursor protein
49. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
50. Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1
51. The E280A presenilin I Alzheimer mutation produces increased Aβ 42 deposition and severe cerebellar pathology
52. Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice
53. The presenilin 2 mutation (N141I) linked to familial Alzheimer disease (volga German families) increases the secretion of amyloid β protein ending at the 42nd (or 43rd) residue
54. Peptidomimetic probes and molecular modeling suggest that Alzheimer's γ-secretase is an intramembrane-cleaving aspartyl protease
55. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons
56. The role of cholesterol in the biosynthesis of β-amyloid
57. Modulation of secreted β-amyloid precursor protein and amyloid β-peptide in brain by cholesterol
58. Cholesterol-dependent generation of a seeding amyloid β-protein in cell culture
59. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10"
60. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ 42 and Aβ 40 in vitro and in vivo"
61. Cholesterol modulates α-secretase cleavage of amyloid precursor protein
62. Statins and the risk of dementia
63. Amyloid diseases: Abnormal protein aggregation in neurodegeneration
64. Amyloid fibril formation requires a chemically discriminating nucleation event: Studies of an amyloidogenic sequence from the bacterial protein osmb
65. Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins
66. Recognition sequence design for peptidyl modulators of β-amyloid aggregation and toxicity
67. Modified-peptide inhibitors of amyloid β-peptide polymerization
68. Controlling polymerization of β-amyloid and prion-derived peptides with synthetic small molecule ligands
69. A short synthesis of the β-amyloid aggregation inhibitor 3-P-toluoyl-2 [4′-(3-diethylaminopropoxy)-phenyl]-benzofuran
70. Vitamin E protects nerve cells from amyloid β protein toxicity
71. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide
72. 2+ channels: A possible involvement of free radicals
73. Protective effect of transforming growth factor-β 1 on β-amyloid neurotoxicity in rat hippocampal neurons
74. The role of estrogen in the treatment and prevention of dementia: Introduction
75. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects
76. Role of estrogen replacement therapy in memory enhancement and the prevention of neuronal loss associated with Alzheimer's disease
77. 17 α-estradiol exerts neuroprotective effects on SK-N-SH cells
78. 17-β estradiol protects neurons from oxidative stress-induced cell death in vitro
79. Neuroprotection against oxidative stress by estrogens: Structure-activity relationship
80. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid β-peptide toxicity in hippocampal neurons
81. Antioxidant and prooxidant behavior of flavonoids: Structure-activity relationships
82. Commonly occurring plant flavonoids have estrogenic activity
83. Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (humulus lupulus) in human cancer cell lines
84. Anti-oxidant properties of hydroxy-flavones
85. Inhibition of camp-phosphodiesterase by biflavones of ginkgo biloba in rat adipose tissue
86. The importance of inflammatory mechanisms in Alzheimer disease
87. Inflammation of the brain in Alzheimer's disease: Implications for therapy
88. Microglia and Alzheimer's disease
89. The brain's immune system
90. Microglia in degenerative neurological disease
91. The inflammatory response system of brain: Implications for therapy of Alzheimer and other neurodegenerative diseases
92. Anti-inflammatory agents as a therapeutic approach to Alzheimer's disease
93. Inflammation and Alzheimer's disease
94. Clinical trial of indomethacin in Alzheimer's disease
95. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease
96. Inflammation and Alzheimer's disease: Mechanisms and therapeutic strategies
97. Risk of Alzheimer's disease and duration of NSAID use
98. Nonsteroidal anti-inflammatory drug use and Alzheimer-Type pathology in aging
99. Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures
100. Senile plaques stimulate microglia to release a neurotoxin found in Alzheimer brain
101. Interaction of Alzheimer β-amyloid peptide with the human monocytic cell line THP-1 results in a protein kinase C-dependent secretion of tumor necrosis factor-α
102. β-amyloid-induced IL-1 β release from an activated human monocyte cell line is calcium- and G-protein-dependent
103. Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia
104. β-amyloid fibrils activate parallel mitogen-activated protein kinase pathways in microglia and THPI monocytes
105. Beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease
106. Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of β-amyloid and prion proteins
107. Inflammatory mechanisms in Alzheimer's disease: Inhibition of β-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARγ agonists
108. β-amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis
109. β-amyloid protein-dependent nitric oxide production from microglial cells and neurotoxicity
110. The role of the immune system in neurodegenerative disorders
111. Anti-inflammatory drugs in the fight against Alzheimer's disease
112. The effect of aspirin and nonsteroidal anti-inflammatory drugs on prostaglandins
113. Scientific rationale for specific inhibition of COX-2
114. Cyclooxygenase in biology and disease
115. Roles of COX-1 and COX-2
116. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs
117. Anti-inflammatory drugs and their mechanism of action
118. Cyclooxygenases and the central nervous system
119. Nonsteroidal antiinflammatory drugs-differences and similarities
120. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs
121. Peroxisome proliferator-activated receptors α and γ are activated by indomethacin other non-steroidal anti-inflammatory drugs
122. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
123. TGF-β1 promotes microglial amyloid-β clearance and reduces plaque burden in transgenic mice
124. Microglia as mediators of inflammatory and degenerative diseases
125. Translating cell biology into therapeutic advances in Alzheimer's disease
126. Production of intracellular amyloid-containing fragments in hippocampal neurons expressing human amyloid precursor protein and protection against amyloidogenesis by subtle amino acid substitutions in the rodent sequence
127. Human and rodent Alzheimer β-amyloid peptides acquire distinct conformations in membrane-mimicking solvents
128. Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis
129. Amyloid precursor protein in guinea pigs-complete Cdna sequence and alternative splicing
130. Expression in brain of amyloid precursor protein mutated in the α-secretase site causes disturbed behavior, neuronal degeneration and premature death in transgenic mice
131. Aggressive behaviour in transgenic mice expressing APP is alleviated by serotonergic drugs
132. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain
133. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein
134. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice
135. Amyloid precursor protein processing and Aβ42 deposition in a transgenic mouse model of Alzheimer disease
136. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
137. Familial Alzheimer's disease-linked presenilin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo
138. Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins
139. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes